Aarhus University Seal / Aarhus Universitets segl

Jens Christian Jensenius

Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus. / Messias-Reason, I; Bosco, DG; Nisihara, RM; Jakobsen, LH; Petzl-Erler, ML; Jensenius, Jens Christian.

In: Clinical and Experimental Dermatology. Supplement, Vol. 33, 2008, p. 495-7.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Messias-Reason, I, Bosco, DG, Nisihara, RM, Jakobsen, LH, Petzl-Erler, ML & Jensenius, JC 2008, 'Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus.', Clinical and Experimental Dermatology. Supplement, vol. 33, pp. 495-7.

APA

Messias-Reason, I., Bosco, DG., Nisihara, RM., Jakobsen, LH., Petzl-Erler, ML., & Jensenius, J. C. (2008). Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus. Clinical and Experimental Dermatology. Supplement, 33, 495-7.

CBE

Messias-Reason I, Bosco DG, Nisihara RM, Jakobsen LH, Petzl-Erler ML, Jensenius JC. 2008. Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus. Clinical and Experimental Dermatology. Supplement. 33:495-7.

MLA

Messias-Reason, I et al. "Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus.". Clinical and Experimental Dermatology. Supplement. 2008, 33. 495-7.

Vancouver

Messias-Reason I, Bosco DG, Nisihara RM, Jakobsen LH, Petzl-Erler ML, Jensenius JC. Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus. Clinical and Experimental Dermatology. Supplement. 2008;33:495-7.

Author

Messias-Reason, I ; Bosco, DG ; Nisihara, RM ; Jakobsen, LH ; Petzl-Erler, ML ; Jensenius, Jens Christian. / Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus. In: Clinical and Experimental Dermatology. Supplement. 2008 ; Vol. 33. pp. 495-7.

Bibtex

@article{387c5f00896511ddbd84000ea68e967b,
title = "Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus.",
abstract = "Endemic pemphigus foliaceus (EPF) is an autoimmune disease, which occurs in Brazil and other regions of South America. Mannose-binding lectin (MBL) and MBL-associated serine protease (MASP-2) play a key role in innate immunity, and its deficiency has been related to increased susceptibility to infection and autoimmune diseases. MBL and MASP-2 serum levels were measured in 114 patients with EPF and in 100 healthy individuals in Brazil. MBL and MASP-2 levels were measured by sandwich assays (time-resolved immunofluorimetic assay) using monoclonal antibodies. No difference was observed in the MBL level in patients with EPF compared with controls [mean +/- SEM 1230.07 +/- 132.18 ng/mL (median 789.0 ng/mL) vs. 1036.98 +/- 117.99 ng/mL (median 559.5 ng/mL), P = 0.32]. Non-significant lower MASP-2 levels were observed in EPF [274.34 +/- 15.66 ng/mL (median 239.5 ng/mL ) vs. 304.72 +/- 15.28 ng/mL [median 261.0 ng/mL ), P = 0.06]. MBL deficiency (< 10 ng/mL) or MASP-2 deficiency (< 100 ng/mL) did not differ significantly between patients and controls. These data indicate that MBL and MASP-2 deficiency are not associated with susceptibility to EPF.",
author = "I Messias-Reason and DG Bosco and RM Nisihara and LH Jakobsen and ML Petzl-Erler and Jensenius, {Jens Christian}",
year = "2008",
language = "English",
volume = "33",
pages = "495--7",
journal = "Clinical and Experimental Dermatology. Supplement",
issn = "0966-3487",
publisher = "Wiley-Blackwell Publishing Ltd",

}

RIS

TY - JOUR

T1 - Circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease 2 in endemic pemphigus foliaceus.

AU - Messias-Reason, I

AU - Bosco, DG

AU - Nisihara, RM

AU - Jakobsen, LH

AU - Petzl-Erler, ML

AU - Jensenius, Jens Christian

PY - 2008

Y1 - 2008

N2 - Endemic pemphigus foliaceus (EPF) is an autoimmune disease, which occurs in Brazil and other regions of South America. Mannose-binding lectin (MBL) and MBL-associated serine protease (MASP-2) play a key role in innate immunity, and its deficiency has been related to increased susceptibility to infection and autoimmune diseases. MBL and MASP-2 serum levels were measured in 114 patients with EPF and in 100 healthy individuals in Brazil. MBL and MASP-2 levels were measured by sandwich assays (time-resolved immunofluorimetic assay) using monoclonal antibodies. No difference was observed in the MBL level in patients with EPF compared with controls [mean +/- SEM 1230.07 +/- 132.18 ng/mL (median 789.0 ng/mL) vs. 1036.98 +/- 117.99 ng/mL (median 559.5 ng/mL), P = 0.32]. Non-significant lower MASP-2 levels were observed in EPF [274.34 +/- 15.66 ng/mL (median 239.5 ng/mL ) vs. 304.72 +/- 15.28 ng/mL [median 261.0 ng/mL ), P = 0.06]. MBL deficiency (< 10 ng/mL) or MASP-2 deficiency (< 100 ng/mL) did not differ significantly between patients and controls. These data indicate that MBL and MASP-2 deficiency are not associated with susceptibility to EPF.

AB - Endemic pemphigus foliaceus (EPF) is an autoimmune disease, which occurs in Brazil and other regions of South America. Mannose-binding lectin (MBL) and MBL-associated serine protease (MASP-2) play a key role in innate immunity, and its deficiency has been related to increased susceptibility to infection and autoimmune diseases. MBL and MASP-2 serum levels were measured in 114 patients with EPF and in 100 healthy individuals in Brazil. MBL and MASP-2 levels were measured by sandwich assays (time-resolved immunofluorimetic assay) using monoclonal antibodies. No difference was observed in the MBL level in patients with EPF compared with controls [mean +/- SEM 1230.07 +/- 132.18 ng/mL (median 789.0 ng/mL) vs. 1036.98 +/- 117.99 ng/mL (median 559.5 ng/mL), P = 0.32]. Non-significant lower MASP-2 levels were observed in EPF [274.34 +/- 15.66 ng/mL (median 239.5 ng/mL ) vs. 304.72 +/- 15.28 ng/mL [median 261.0 ng/mL ), P = 0.06]. MBL deficiency (< 10 ng/mL) or MASP-2 deficiency (< 100 ng/mL) did not differ significantly between patients and controls. These data indicate that MBL and MASP-2 deficiency are not associated with susceptibility to EPF.

M3 - Journal article

VL - 33

SP - 495

EP - 497

JO - Clinical and Experimental Dermatology. Supplement

JF - Clinical and Experimental Dermatology. Supplement

SN - 0966-3487

ER -